CN Patent

CN105209460A — 作为突变idh抑制剂的3-嘧啶-4-基-噁唑烷-2-酮化合物

Assigned to Novartis AG · Expires 2015-12-30 · 10y expired

What this patent protects

本发明涉及式(I)或其药学上可接受的盐，其中R 1 、R 2a 、R 2b 和R 3 -R 7 如文中所述。本发明还涉及含有式(I)化合物的组合物、所述化合物在抑制具有新变体活性的突变IDH蛋白质中的用途。本发明还涉及式(I)化合物在治疗与这类突变IDH蛋白质相关的疾病或障碍、包括但不限于细胞增殖性障碍如癌症中的用途。

USPTO Abstract

本发明涉及式(I)或其药学上可接受的盐，其中R 1 、R 2a 、R 2b 和R 3 -R 7 如文中所述。本发明还涉及含有式(I)化合物的组合物、所述化合物在抑制具有新变体活性的突变IDH蛋白质中的用途。本发明还涉及式(I)化合物在治疗与这类突变IDH蛋白质相关的疾病或障碍、包括但不限于细胞增殖性障碍如癌症中的用途。

Drugs covered by this patent

Patent Metadata

Patent number
CN105209460A
Jurisdiction
CN
Classification
—
Expires
2015-12-30
Drug substance claim
No
Drug product claim
No
Assignee
Novartis AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.